Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT03439839 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis

Interventions

DRUG: iptacopan
COMBINATION_PRODUCT: Standard of Care

Sponsor

Novartis Pharmaceuticals